You have 9 free searches left this month | to do more

nivolumab

Nivolumab is a drug used to treat Melanoma, Renal Cell Carcinoma, Metastatic Melanoma, and other conditions. Nivolumab is being actively studied in 633 studies and prior, has been studied in 112.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionIvan S Moiseev
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterInna Chen, MD
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDana Farber Cancer InstituteTheodore Sunki Hong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Recruiting
  • Melanoma Stage III
  • Melanoma
  • Durham, North Carolina
  • +1 more
2022-03-25
Mar 25, 2022
D
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
Recruiting
  • Melanoma
  • Vidutolimod (CMP-001)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2022-03-25
Mar 25, 2022
I
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Nivolumab + Nab-paclitaxel
  • Nivolumab
  • Milan, MI, Italy
    Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and
2022-03-28
Mar 28, 2022
B
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Combination 5-azacytidine and nivolumab
  • +2 more
  • (no location specified)
2022-03-29
Mar 29, 2022
D
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2022-03-28
Mar 28, 2022
C
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
Not yet recruiting
  • Gastric Cancer
  • Chemotherapy Effect
  • Nivolumab plus SOX
  • +2 more
  • (no location specified)
2022-01-07
Jan 7, 2022
C
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Nivolumab
  • Oral Azacitidine
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
B
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors - 2021
Completed
  • Solid Tumors
  • Nivolumab
  • Guangzhou, Guangdong, China
  • +1 more
2022-03-14
Mar 14, 2022
Y
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Recruiting
  • Recurrent/Metastatic Carcinosarcoma
  • nivolumab
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
2022-02-03
Feb 3, 2022
N
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Active, not recruiting
  • Ann Arbor Stage III Lymphoma
  • +4 more
  • Bethesda, Maryland
  • +2 more
2022-04-05
Apr 5, 2022
D
NeoVax + CDX-301 and Nivolumab in Advanced Melanoma
Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2022-03-16
Mar 16, 2022
S
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Active, not recruiting
  • Neuroendocrine Tumors
  • Carcinoid Tumor
  • Baltimore, Maryland
    Johns Hopkins Medical Institution
2021-12-15
Dec 15, 2021
T
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
Recruiting
  • Breast Cancer
  • Amsterdam, Netherlands
    NKI-AVL
2022-03-31
Mar 31, 2022
D
Nivolumab Plus Ipilimumab in Thyroid Cancer
Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-02-18
Feb 18, 2022
S
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Recruiting
  • Microsatellite Stable (MSS) Colorectal Adenocarcinomas
  • Colorectal Adenocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022
R
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Active, not recruiting
  • Renal Cell Carcinoma
  • Washington, District of Columbia
  • +1 more
2022-01-10
Jan 10, 2022
S
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022
D
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-07-22
Jul 22, 2021
S
ASCT With Nivolumab in Patients With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Saint Petersburg, Russian Federation
    Boris V Afanasyev, MD, Prof.
2022-04-04
Apr 4, 2022
A
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Hypofractionated Radiation Therapy (HFRT)
  • +2 more
  • Lancaster, Pennsylvania
  • +1 more
2022-03-30
Mar 30, 2022
T
Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
Active, not recruiting
  • Breast Cancer
  • Nivolumab
  • +4 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
2022-03-21
Mar 21, 2022
I
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Nivolumab
  • PD-L1/IDO peptide vaccine
  • Herlev, Denmark
  • +1 more
2022-03-15
Mar 15, 2022
N
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
Suspended
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022
A
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Active, not recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Nivolumab
  • Amsterdam, Noord-Holland, Netherlands
    VU University medical center
2021-10-06
Oct 6, 2021
S
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
Recruiting
  • Nasopharyngeal Carcinoma
  • Nivolumab
  • +2 more
  • San Francisco, California
  • +1 more
2022-02-07
Feb 7, 2022